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Letter to the Editor
With interest we read the article by Louw et al. about measuring
coenzyme-Q(CoQ)-levels in frozen muscle biopsies and work-up for the
causes CoQ-deficiency.in 76 biopsies from patients with a suspected
respiratory chain defect(RCD) [1]. We have the following comments
and concerns.
Complex-II(CII) and complex III-(CIII)-deficiency not necessarily
reflect primary CoQ-deficiency. CII/CIII-deficiency may also occur in
patients with other RCD defects [2]. These RCD defects may go along
with secondary CoQ-deficiency.
Patients with a MID or with CoQ-deficiency may require substitu-
tion with CoQ [3]. How many of the included patients were under a
CoQ-therapy, necessitating the exclusion of such patients from the
study.
Did the authors also apply their reference limits to patients with
genetically confirmed primary CoQ-deficiency? Possibly, CoQ-levels are
normal at least in some of these patients due to upregulation of CoQ-
production in cellular compartments other than the mitochondria.
Since muscle CoQ-levels may also depend on lactate production [4],
we should be informed how many of the included patients had in fact
lactic acidosis.
Additionally, it would be useful to know which drugs the included
patients were taking at the time of the muscle biopsy. Not only CoQ-
substitution may influence muscle CoQ-levels, but also drugs, such as
statins [5].
The physical status of a patient including muscle mass, physical
fitness, and disabilities may further influence CoQ-levels. Thus, the
severity of the muscular involvement, the patients' ability to ambulate,
and the physical fitness should be reported. In which stage of the dis-
ease did the included patients undergo muscle biopsy? How many were
disabled and dependent on a walking aid or a wheel chair and how
many were bedridden?
Overall, this interesting study could be more meaningful by dis-
cussing the dependency of muscle CoQ on drugs, lactic acidosis, and the
individual fitness. Upregulation of CoQ-production in compartments
other than the mitochondria may further influence muscle CoQ.
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